Vaccine | No Adjuvant | ||
---|---|---|---|
N = 67 | N = 123 | ||
N(%)/Mean(SD) | N(%)/Mean(SD) | P-Value | |
Age | 56.00 (13.44) | 60.05 (16.44) | 0.086 |
Sex | 0.2854 | ||
Female | 31 (46.27) | 47 (38.21) | |
Male | 36 (53.73) | 76 (61.79) | |
Thicknessa | 3.12 (4.43) | 4.18 (4.46) | 0.009 |
Ulceration | 0.3511 | ||
Present | 23 (34.33) | 52 (42.28) | |
Absent | 32 (47.76) | 57 (46.34) | |
Undetermined | 12 (17.91) | 14 (11.38) | |
AJCC Stage | 0.0082 | ||
IIIA | 15 (22.39) | 48 (39.02) | |
IIIB | 26 (38.81) | 51 (41.46) | |
IIIC | 26 (38.81) | 24 (19.51) | |
Histologic Subtype | 0.0435 | ||
Nodular | 17 (25.37) | 52 (42.28) | |
Superficial Spreading | 12 (17.91) | 26 (21.14) | |
Other | 6 (8.96) | 13 (10.57) | |
Undetermined | 32 (47.76) | 32 (26.02) | |
Other Adjuvant Treatment | – | ||
GM-CSF | 6 (8.96) | Not Applicable | |
Interferon | 6 (8.96) | ||
Isolated Limb Infusion | 3 (4.48) | ||
Radiation | 22 (32.84) |
amissing values for thickness: vaccine: 10; no adjuvant: 13
athickness not normally-distributed, log-transformed for statistical test